Liquent Unveils the Results of its Regulatory Affairs Trends Survey

HORSHAM, Pa., July 28 /PRNewswire/ -- Liquent, Inc. ("Liquent") is pleased to announce the findings of its 2009 Liquent Regulatory Affairs Trends Survey. The survey attracted respondents from across the globe representing small, medium and large life sciences companies and provides a unique insight into emerging and future trends in regulatory product management usage and adoption.

Liquent's annual survey is one of the leading resources of trends impacting regulatory affairs and operations professionals.  The survey provides insight into how pharmaceutical regulatory professionals use technology today and how they plan to harness technology in the future.  It is recognized as the premier benchmark of global regulatory submission trends in the market today. The survey provides exclusive insight into the emerging and future trends of regulatory product management needs for the life science market. The Liquent 2009 survey yielded a variety of responses from 150 Regulatory Affairs professionals.

This year's survey concentrated on four key areas: Technology Usage Trends, including submission publishing, registration management and other technologies, Document Management System usage, Regulatory Operations Outsourcing trends, and Regulatory trends including adoption of electronic Common Technical Document (eCTD) and other regulatory submission formats.

Key survey findings include:

Technology Usage:

--88% of respondents are expecting their use of publishing software to increase over the next 2 years.  This figure has increased slightly since 2008 (82%).

Regulatory Outsourcing:

--31% of respondents are outsourcing study report writing and 18% are outsourcing study report publishing.  Up from 22% and 9% respectively in 2008.

Regulatory Trends

-- 14% of respondents plan to adopt the HL7's Regulated Product Submission (RPS) format within the next two years. This figure has increased significantly since 2008 (7%).  

"Every year our regulatory trends survey attracts a varied group of respondents from a diverse number of organizations throughout the globe, and this year was no different," said Jim Nichols, Vice President, Strategy at Liquent.  "The findings reaffirm our belief that the continued standardization of submission and data formats is making it easier to share critical information both internally and with the regulatory authorities."

Liquent will be presenting its full results later this year as part of their monthly webinar series.  For additional information please contact Liquent at [email protected].

Liquent is owned by Marlin Equity Partners a Los Angeles, California-based private investment firm with over $1 billion of capital under management.

About Liquent, Inc.

Liquent regulatory solutions provide software and related regulatory and clinical services for the life sciences industry. These solutions and services help ensure clients meet the strict standards of regulatory authorities across the world helping them achieve quality, accuracy, and data integrity to deliver regulatory reports and submissions reliably and on time.

As a result, global life sciences companies, small tier to large tier, rely on Liquent regulatory solutions to  provide the technology and services to compress the regulatory submissions and approval process, improving speed to market, cost control, and productivity, all of which contribute to ensuring patients' and physicians' timely access to new drugs. Over the last decade, thousands of regulatory submissions have been produced using Liquent world-class products and expert services. For more information please visit, www.liquent.com.

SOURCE Liquent, Inc.